Clinical trial
Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety…
NCT00191022 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191022 |
|---|---|
| Title | Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder |
| Official title | A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Social Phobia |
| Intervention type | Drug |
| Interventions | LY686017, paroxetine, placebo |
| Enrollment | 185 |
| Start date | Dec 1, 2004 |
| Completion | Jan 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 13, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: